PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse With Cancer After Allogeneic Stem Cell Transplantation

Cancer Research - United States
doi 10.1158/0008-5472.can-11-0108
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Over-Expression of PD-1 Does Not Predict Leukemic Relapse After Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

EBV-associated Gastric Cancer Evades T-Cell Immunity by PD-1/PD-L1 Interactions

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2018English

Relapse After Allogeneic Stem Cell Transplantation

Expert Review of Hematology
Hematology
2010English

Enhancement of T Cell Immunity to Osteosarcoma Through Modulation of PD-1/PD-L1 Interactions

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

P2.01-82 Neutrophil-To-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak
2018English

Expression of PD-1, PD-L1, and PD-L2 in Posttransplant Lymphoproliferative Disorder After Solid Organ Transplantation

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy